Pulse Biosciences, Inc.
NASDAQ:PLSEMedical - Instruments & Supplies
+$0.97 today
- Market cap
- $3.37B
- Beta
- 1.66
- P/E (TTM)
- -24.0
- EPS (TTM)
- -$1.10
Volume 0.33M
Average 0.31M
PLSE Pre-Tax Margin
Income before tax as a percentage of revenue.
Pulse Biosciences, Inc.NASDAQ: PLSE
Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026
Pre-tax margin at -5681.3%
Pre-tax margin was -5681.3% in Q2 FY2026. On a trailing-twelve-month basis it was -6755.8%. Over 3 fiscal years it narrowed by 12436.7 pp.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -20794.6%
- Year-over-year change
- —
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -20794.6% | — |
| FY2024 | 2024-12-31 | — | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | -8357.9% | -3868.4pp |
| FY2021 | 2021-12-31 | -4489.4% | — |
Pre-Tax Margin vs competitors
How PLSE compares with its peers on the latest reported figures
- PLSE's LTM Jun 2026 pre-tax margin of -6755.8% is the 10th highest of the 11 companies compared; the peer median is -115.9%.
- Over three fiscal years its change of -12436.7 pp compares with a peer median of -0.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Apr 2026 | -6.7% | +15.2 pp | -50.4 pp | |
| LTM Mar 2026 | -6.8% | -2.9 pp | +32.3 pp | |
| LTM Mar 2026 | -26.0% | -5.1 pp | -5.6 pp | |
| LTM Mar 2026 | -39.4% | -39.3 pp | -0.7 pp | |
| LTM Mar 2026 | -60.3% | +41.4 pp | +36100.7 pp | |
| LTM Jan 2026 | -171.6% | -10.2 pp | — | |
| LTM Jun 2026 | -287.1% | -123.4 pp | +99.2 pp | |
| LTM Mar 2026 | -577.4% | -565.0 pp | -435.5 pp | |
| LTM Jun 2026 | -1570.9% | +793.3 pp | -7529.6 pp | |
| LTM Jun 2026 | -6755.8% | — | -12436.7 pp | |
| LTM Jun 2026 | -14938.1% | -9731.6 pp | +48750.4 pp | |
| Peer median (excluding PLSE) | -115.9% | -7.6 pp | -0.7 pp | |
Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.42M | 700K | 0 | 0 | 350K |
| Cost of Revenue | 1.97M | 11.94M | 1.21M | 0 | 1.61M |
| Gross Profit | (550K) | (11.24M) | (1.21M) | 0 | (1.26M) |
| Gross Margin | -38.8% | -1606.3% | — | — | -360.0% |
| Research & Development | 28.64M | 20.84M | 27.8M | 32.34M | 44.72M |
| Selling, General & Admin | 33.82M | 25.97M | 15.78M | 23.92M | 32.03M |
| Operating Expenses | 62.46M | 46.81M | 42.37M | 56.26M | 75.68M |
| Depreciation & Amortization | 1.15M | 1.36M | 1.21M | 1.18M | 1.07M |
| EBITDA | (62.51M) | (57.15M) | (39.9M) | (52.41M) | (71.71M) |
| EBITDA Margin | -4408.6% | -8164.3% | — | — | -20488.6% |
| Operating Income | (63.01M) | (58.06M) | (43.57M) | (56.26M) | (76.94M) |
| Operating Margin | -4443.9% | -8293.9% | — | — | -21982.6% |
| Interest Income | 0 | 0 | 2.46M | 2.67M | 4.21M |
| Interest Expense | 646K | 448K | 1.1M | 0 | 0 |
| Other Income / Expenses | (646K) | (448K) | 1.36M | 2.67M | 4.16M |
| Income Before Tax | (63.66M) | (58.51M) | (42.21M) | (53.59M) | (72.78M) |
| Pre-Tax Margin | -4489.4% | -8357.9% | — | — | -20794.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (63.66M) | (58.51M) | (42.21M) | (53.59M) | (72.78M) |
| Net Margin | -4489.4% | -8357.9% | — | — | -20794.6% |
| EPS (Basic) | (2.28) | (1.72) | (0.88) | (0.92) | (1.08) |
| EPS (Diluted) | (2.28) | (1.72) | (0.88) | (0.92) | (1.08) |
| Weighted Avg Shares | 27.96M | 33.94M | 48.04M | 58.4M | 67.4M |
| Weighted Avg Shares (Diluted) | 27.96M | 33.94M | 48.04M | 58.4M | 67.4M |
Pulse Biosciences, Inc.
NASDAQ:PLSE
Intrinsic Alpha fair value
Locked
Current Price
$45.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.